I'm not suggesting anything of the sort. I believe their reasons for halting the trial are genuine and as stated. What I'm saying is, given those challenges which will not be resolved with the FDA any time soon, it is unlikely that PW will remain a priority going forward and will most likely be pursued by whoever acquires NEU.
NEU Price at posting:
$23.97 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)